Streetbeat News

Regulatory

SNY

Sanofi's Frexalimab Phase 2 data shows a 41% reduction in a key biomarker of nerve cell damage in relapsing MS, with significant drops in plasma neurofilament light chain levels after 48 weeks. The data supports its potential as a high-efficacy, disease-modifying treatment. Phase 3 studies are underway.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:41 pm

NXPI

VGK

The European Union has issued a warning that its chipmakers may lose market share in China. This development could have significant implications for companies like NXP Semiconductors (NXPI) and the Vanguard FTSE Europe ETF (VGK).

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:36 pm

CMND

Clearmind Medicine shares are trading higher following the announcement of a patent approval in Hong Kong for its MEAI-based binge behavior regulator program.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:32 pm

JNJ

Johnson & Johnson announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study, showing significant improvement in patients with generalized myasthenia gravis. The study demonstrated superiority in activities of daily living over placebo when added to standard care over 24 weeks. These results will be presented at the European Academy of Neurology 2024 Congress and included in regulatory submissions later this year.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:31 pm

GOOGL

META

SNAP

TikTok has applied for the 'Genie' trademark in the U.S. for an AI chatbot, indicating its move into the AI space. This development could impact competitors like Meta, Google, and Snap, who are also investing in AI technologies.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:28 pm

BTCUSD

ETHUSD

Kraken Co-Founder Jesse Powell has endorsed Donald Trump, the 'only pro-crypto major party candidate,' and donated $1 million in Ethereum to his campaign. Trump has shown support for the crypto sector but has yet to propose specific policies.

Portfolio Pulse from Murtuza Merchant

June 28, 2024 | 3:24 pm

JNJ

Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Balversa (Erdafitinib) for the treatment of adult patients.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 2:58 pm

APLS

Apellis shares are trading lower after the company announced that the CHMP has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 2:55 pm

PTCT

PTC Therapeutics shares are trading lower after the CHMP issued a negative opinion on Translarna following the European Commission's request for review.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 2:52 pm

MSFT

Microsoft's $13 billion investment in OpenAI is under scrutiny by the EU's antitrust regulators due to concerns about the exclusivity of Microsoft's cloud technology for OpenAI's use. The EU will gather more information from Microsoft's competitors and customers, which could lead to formal investigations if anti-competitive behavior is found. Similar inquiries have been made by the U.K. and U.S. regulators.

Portfolio Pulse from Shivani Kumaresan

June 28, 2024 | 2:50 pm